Asthma Chip Reveals Treatable Subtype in 70% of Patients
A study by KL Krems and MedUni Vienna identifies a majority of asthma cases as allergic and opens access to effective, affordable immunotherapy.
Dragana Gordic - stock.adobe.com(firmenpresse) - Krems (Austria), 1 September 2025 – A simple blood test could make asthma treatment more precise, more effective – and potentially more affordable. Researchers from Karl Landsteiner University of Health Sciences (KL Krems) and the Medical University of Vienna (MedUni Vienna) have developed a molecular allergy chip that detects allergic asthma in individual patients. Applied to samples from the large-scale LEAD cohort, the test showed that more than 70% of participants with asthma had sensitization to specific airborne allergens. For these patients, a proven, targeted therapy already exists: allergen-specific immunotherapy (AIT). The findings pave the way for more personalized treatment strategies, allowing physicians to go beyond symptom control and offer a disease-modifying option.
Asthma affects roughly 300 million people worldwide and ranks among the most burdensome chronic lung diseases. Despite substantial advances in medicine, most patients still receive uniform symptomatic treatment: inhaled corticosteroids and bronchodilators. In recent years, expensive biologics have been added for selected cases, raising concerns about the sustainability of asthma care. Yet for allergic asthma – the most common form – a well-established and cost-effective option exists: allergen-specific immunotherapy. What has been lacking is a practical, accurate way to identify who stands to benefit. The newly developed asthma chip offers exactly that.
Allergy Profile at a Glance
Developed by Dr. Huey-Jy Huang and colleagues at the Scientific Working Group Allergology and Immunology at KL Krems, in collaboration with MedUni Vienna and others, the chip contains 63 allergen molecules from key airborne sources such as pollens, dust mites, molds and animal dander. When tested with serum samples from 436 asthma patients in the LEAD study (Lung, hEart, sociAl, boDy), the chip identified specific IgE sensitizations in more than 70% of cases. These individuals had allergic asthma — and showed clinical characteristics that clearly distinguished them from non-allergic patients: younger age, better lung function, and less reliance on corticosteroids, despite fewer signs of inflammation.
“These results show that a large share of asthma adult patients has allergic asthma – and that we can identify them quickly and precisely,” says Prof. Rudolf Valenta from the MedUni Vienna, head of the Scientific Working Group Allergology and Immunology at KL Krems and senior co-author of the study. “This is important because allergic asthma can be treated causally, not just symptomatically – using allergen-specific immunotherapy.” AIT is a well-established approach in allergy medicine. It works by gradually desensitizing the immune system to the specific allergens causing symptoms. When based on precise diagnosis, it ca significantly reduce exacerbations and improve long-term outcomes.
Pure Results
Unlike conventional extract-based tests, the chip uses purified allergen molecules. This enables clear distinction between true sensitizations and cross-reactions – a key requirement for successful immunotherapy. The method supports individualised treatment decisions and could be particularly valuable in younger patients, where early intervention can alter the course of the disease.
With the prevalence of asthma rising and healthcare systems under financial pressure, tools that help allocate treatments more precisely are urgently needed. “We hope this diagnostic approach will find its way into routine clinical practice,” says Prof. Valenta. “It could allow many patients to benefit from an effective, affordable form of immunotherapy – and help reduce unnecessary use of costly biologics.” The study demonstrates how integrating molecular diagnostics into asthma care could help shift the current paradigm – from blanket symptom management to tailored, evidence-based strategies.
Original Publication: Molecular IgE sensitization profiling with micro-arrayed allergen molecules in adult patients with asthma from the LEAD cohort: A precision medicine approach. HJ Huang, R Breyer-Kohansal, K Niespodziana, CJM Lim, MK Breyer, R Valenta, S Hartl, Allergochip Working Group. Allergy, 2025; 0:1–15. https://doi.org/10.1111/all.70017
https://kris.kl.ac.at/en/publications/molecular-ige-sensitization-profiling-with-micro-arrayed-allergen
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Karl Landsteiner University of Health Sciences (09/2025)
The Karl Landsteiner University of Health Sciences (KL Krems) is an educational and research institution on the Campus Krems and recognised throughout Europe. KL Krems offers modern, demand-oriented education and continuing education in medicine and psychology as well as a PhD programme in Mental Health and Neuroscience. The flexible educational programme is tailored to the needs of students, the requirements of the labour market and the challenges of science. The three university hospitals in Krems, St. Pölten and Tulln and the MedAustron Ion Therapy and Research Centre in Wiener Neustadt guarantee clinical teaching and research of the highest quality. In its research, KL Krems focuses on interdisciplinary fields with high relevance to health policy - including biomechanics, molecular oncology, mental health and neuroscience as well as the topic of water quality and the associated health aspects. KL Krems was founded in 2013 and accredited by the Austrian Agency for Quality Assurance and Accreditation (AQ Austria).
Scientific Contact
Huey-Jy Huang, PhD
Scientific Working Group Allergology and Immunology
Karl Landsteiner University of Health Sciences
Dr.-Karl-Dorrek-Straße 30
3500 Krems / Austria
T +43 2732 72090 571
E huey-jy.huang(at)kl.ac.at
W https://www.kl.ac.at/
Copy Editing & Distribution
PR&D – Public Relations for Research & Education
Dr. Barbara Bauder-Jelitto
Kollersteig 68
3400 Klosterneuburg / Austria
M +43 664 1576 350
E bauder(at)prd.at
L https://www.linkedin.com/company/prd-public-relations-für-forschung-bildung
W https://www.prd.at/
Datum: 01.09.2025 - 17:03 Uhr
Sprache: Deutsch
News-ID 726098
Anzahl Zeichen: 4646
contact information:
Contact person: Dr. Till C. Jelitto
Town:
Klosterneuburg, Austria
Kategorie:
Healthcare & Medical
Typ of Press Release: Success
type of sending: don't
Date of sending: 01.09.2025
Diese Pressemitteilung wurde bisher 91 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Asthma Chip Reveals Treatable Subtype in 70% of Patients"
steht unter der journalistisch-redaktionellen Verantwortung von
PR&D – Public Relations ?for Research & Education (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
